Latest Diabetes News
"That [weight loss] is not what this drug was designed to do, but it's a very attractive additional benefit," said study co-author Richard DiMarchi, a research chemist at Indiana University in whose lab the drug was created.
The injectable medication is based on a single molecule that combines the properties of two hormones that send chemical signals to the pancreas, said DiMarchi.
People with type 2 diabetes have lower levels of these pancreas-signaling hormones, which are known as incretins, explained Dr. John Anderson, president of medicine and science at the American Diabetes Association.
"The incretin defect in type 2 diabetes is well known, and it's only within the last few years we have had agents to treat it," Anderson said.
"In this study, the degree of gastrointestinal discomfort is much more modest than is experienced in conventional drugs," DiMarchi said. "We get beneficial glycemic control with this combination drug, and it seems to be with less adverse drug effect."
The medication combines the action of the hormones GLP-1 and GIP. Current diabetes medications of this sort target GLP-1 receptors in the body; studies involving GIP have produced mixed results.
GLP is known to suppress appetite, and DiMarchi said the weight loss observed in mice might be occurring because the second hormone, GIP, is somehow "turbo-charging" that appetite suppression.
In the mouse trials, a drug based on GLP-1 alone decreased body weight by an average 15 percent. But the new drug combining GLP-1 and GIP decreased body weight by nearly 21 percent, as well as controlling blood glucose and decreasing appetite.
A six-week human trial involving 53 patients with type 2 diabetes found that the medication effectively controlled their blood sugar levels. However, the researchers did not note any change in weight during the relatively short study period.
The higher potency of the combined molecule suggests it could be administered at lower doses than other incretin-based medications, reducing side effects and making the drug easier to take.
The next step will be to hold human trials in which the new medication is administered alongside a current drug, to compare effectiveness, he said.
Roche, which makes the drug, funded the study. It will be up to five years before the drug might receive approval from the U.S. Food and Drug Administration, DiMarchi said.
The FDA issued a safety alert in March regarding incretin diabetes drugs, citing unpublished findings that suggest an increased risk of pancreatitis and pancreatic cancer by using the drugs. The American Diabetes Association has called for an independent review of these medications to evaluate these claims.
The initial findings regarding the combination medication are "promising, I think," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City.
"The question now becomes the weight loss in human subjects, how much weight loss, because that's going to be preferable if there will be weight loss," Mezitis said. "The good thing is this agent is not only treating diabetes but also is treating obesity. People would be losing weight and also maintaining glucose control."
Noting that the human trial involved only a handful of people for a short period of time, Anderson said he looks forward to seeing further research on the combination therapy.
"While it's an interesting concept and something that could be very promising, we're a long way from knowing whether targeting both hormone receptors will be incrementally better or a lot better," he said. "There's obviously a lot they're going to have to do with this molecule from this point forward."
The study findings were published Oct. 30 in the journal Science Translational Medicine.
Copyright © 2013 HealthDay. All rights reserved.